Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short
BioSpace
Although Edgewise Therapeutics' hypertrophic cardiomyopathy asset missed expectations, Truist Securities called the data "excellent," leaning on a safety profile that could eliminate the need for risk
pharminent
June 17, 2026 (Last updated: June 17, 2026)
BioSpace
Although Edgewise Therapeutics’ hypertrophic cardiomyopathy asset missed expectations, Truist Securities called the data “excellent,” leaning on a safety profile that could eliminate the need for risk
